Kite partner HiFiBiO closes $67M round for preclinical antibody candidates churned out of single-cell analytics platform
A fledgling biotech with operations spanning (the American) Cambridge, Paris and Shanghai has just bagged $67 million to bring its pipeline of cancer and autoimmune disease-fighting antibodies into the clinic.
Despite its relatively low profile, HiFiBiO boasts of partnerships with well-known players, from pilot projects with Pfizer and J&J in its early days to more recent collaborations with Takeda and Gilead’s Kite subsidiary.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.